

## Technology Advisory Committee D Interests Register

**Topic: Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]**

**Publication Date: 8 May 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Will Sullivan	TAC Committee Member	Direct- financial	In his role as a consultant, Will's employer is paid for him to provide consultancy services to various pharmaceutical companies. In the last 12 months, none of these companies are potential comparator companies for this topic.	28/08/2024	It was agreed that Dr Sullivan's declaration would not prevent them from participating in discussions on this appraisal.
Dr Matthew Bradley	TAC Committee Member	Direct- financial	Dr Bradley holds shares in AstraZeneca, who are the submitting company for this appraisal	30/08/2024	It was agreed that Dr Bradley's declaration would prevent them from participating in discussions on this appraisal.
Shobhit Baijal	Clinical Expert	Direct – financial	Shobhit has done paid consultancy work for AstraZeneca	03/10/2024	It was agreed that Shobhit's declaration would not prevent them from providing expert advice to the committee.